menu
    • menu

    Company profile for Alpha Biopharma

    NEW Drugs in Dev: 1
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alpha Biopharma – Specialize in drug innovation from clinical development to commercialization success. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drugs. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha Biopharma establishes strategic partner...
    Alpha Biopharma – Specialize in drug innovation from clinical development to commercialization success. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drugs. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha Biopharma establishes strategic partnership with leading international pharmaceutical companies/R&D institutes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alpha BiopharmaChina Flag
    Country
    Country
    China
    Address
    Address
    Unit 02-05, 11/F, East Tower, Raffles City, The Bund, No.1089 Dong Daming Road...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.alphabiopharma.com/en/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alpha Receives NMPA Approval for Zorifertinib Tablets for Lung Cancer
    Alpha Receives NMPA Approval for Zorifertinib Tablets for Lung Cancer

    20 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alpha-biopharma-received-nmpa-approval-for-zorifertinib-tablets-zorifer-the-worlds-first-egfr-tki-for-lung-cancer-with-brain-metastases-302311486.html

    PR NEWSWIRE
    20 Nov 2024
    Share Share
    Alpha Biopharma Submits New Drug Application for Zorifertinib
    Alpha Biopharma Submits New Drug Application for Zorifertinib

    29 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alpha-biopharma-submits-new-drug-application-for-zorifertinib-a-next-generation-egfr-tki-to-treat-egfr-mutated-nsclc-patients-with-cns-metastases-301733086.html

    PR NEWSWIRE
    29 Jan 2023
    Share Share
    Alpha Biopharma Completes EVEREST PII/III Study of Zorifertinib in NSCLC
    Alpha Biopharma Completes EVEREST PII/III Study of Zorifertinib in NSCLC

    24 Aug 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/alpha-biopharma-announces-completion-of-its-everest-phase-iiiii-clinical-study-of-zorifertinib-in-non-small-cell-lung-cancer-patients-with-central-nervous-system-metastases-301611469.html

    PRNEWSWIRE
    24 Aug 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search